All articles by Divya Tirumalaraju

Divya Tirumalaraju

Lilly’s Covid-19 antibody combo EUA expands for post-exposure prophylaxis

The authorisation comes after the US Government resumed the supply of bamlanivimab and etesevimab together.

Biocon Biologics enters strategic collaboration with Serum Institute unit

Biocon Biologics will offer a nearly 15% stake to SILS and will gain access to 100 million vaccine doses.

Health Canada grants full approval to Moderna and Pfizer Covid-19 shots

Both vaccines received Canadian authorisation under an Interim Order in December last year.

BioMarin’s Voxzogo receives EC approval for achondroplasia in children

Voxzogo, which acts on achondroplasia’s underlying pathophysiology, is the first to get approval for this indication in Europe.

Roche to withdraw Tecentriq for one breast cancer indication in US

Based on changes in the mTNBC therapy landscape, FDA does not consider it suitable to continue this indication for Tecentriq.

Pfizer secures provisional approval for Covid-19 vaccine in Australia

Comirnaty is the first Covid-19 vaccine to obtain regulatory approval in Australia, following first full approval by the US FDA.

Amgen to build new $365m manufacturing plant in Ohio, US

With construction planned to commence this year, the new plant will become operational by 2024.

STADA to acquire 16 consumer healthcare brands from Sanofi

The transaction does not cover manufacturing assets and employees related to the brands.

RedHill Biopharma’s opaganib shows activity against Covid-19 variants

The preclinical study assessed the drug’s in vitro effectiveness in blocking the Beta and Gamma SARS-CoV-2 variants.

EC approves Chugai’s Enspryng for NMOSD treatment

The drug, designed using Chugai’s recycling antibody technology, is approved in 54 countries.